The brentuximab vedotin was approved by the FDA in 2011 for treating relapsed HL and systemic anaplastic large cell lymphoma (SALCL).27,28 WT1 (Wilms’ tumor gene 1) peptide-based tumor vaccine was first used in patients with overt leukemia from MDS or MDS with myelofibrosis in the year 2002.29,30 As another rising star in immunotherapy, ICIs have entered the field of treatment for hematologic malignancies due to their great success in solid tumors. This evidence concerns the gene WT1 and myelodysplastic syndrome.